Sunday 18 October 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million. In the quarter to June 2026, EPS grew 35.5% and free cash flow grew 26.7%, each against the same quarter a year earlier.
7.02
0.88
−11.14%
Follow CTNM
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
— | 1.83 | — | — |
P/S ratio |
— | 0.00 | — | — |
P/FCF ratio |
— | 2.26 | — | — |
Altman Z″-Score (non-manufacturers) |
— | 4.74 | — | — |
P/Operating CF |
— | (4.57) | — | — |
P/B ratio |
— | 0.00 | — | — |
Price to Tangible BV |
— | 0.00 | — | — |
EV/Sales |
— | 0.00 | — | — |
EV/EBITDA |
— | 0.00 | — | — |
EV/Operating CF |
— | (4.87) | — | — |
EV/FCF |
— | (5.03) | — | — |
Quick Ratio |
6.26 | 22.83 | 20.53 | 26.98 |
Current Ratio |
6.41 | 23.29 | 20.69 | 27.50 |
Net Debt/EBITDA |
1.95 | (7.76) | 4.02 | 3.88 |
Debt/Assets |
7.80% | 0.36% | 0.68% | 0.00% |
Debt/Equity |
(0.04) | (0.01) | 0.01 | 0.00 |
Asset Turnover |
— | 0.55 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 6.15 | 0.78 | 0.92 |
Capex/Depreciation |
(0.24) | 138.00 | (1.91) | (0.72) |
Interest Coverage |
(58.56) | 77.29 | — | — |
| 0.00% | (3.90%) | (64.95%) | (26.13%) | |
| 0.00% | 3.48% | (24.62%) | (24.51%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(58.76%) | 2.56% | (21.41%) | (23.16%) |
Average Days of Receivables |
— | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 55.21% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 12.64% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 4.44% | 0.00% | 0.00% |
Graham Net Nets |
— | (2.18) | — | — |
Graham Number |
— | 0.00 | — | — |
Earnings Yield |
— | 54.59% | — | — |
Free Cash Flow Yield |
— | 44.16% | — | — |
Revenue per Share |
0.00 | 21.65 | 0.00 | 0.00 |
Operating CF per Share |
(8.97) | 8.38 | (1.70) | (2.00) |
Capex per Share |
(0.05) | (0.18) | (0.03) | (0.01) |
Free Cash Flow per Share |
(9.02) | 8.20 | (1.72) | (2.01) |
Cash per Share |
21.06 | 54.22 | 10.58 | 9.49 |
Shareholders Equity per Share |
(41.56) | (29.42) | 10.23 | 9.42 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(41.56) | (29.42) | 10.23 | 9.42 |
Free Cash Flow |
(20.24) | 18.94 | (33.34) | (55.54) |
Working Capital |
40.84 | 122.22 | 196.41 | 258.17 |
Capital Expenditures |
(0.12) | (0.41) | (0.49) | (0.23) |
Net Current Asset Value |
(95.46) | (70.62) | 191.61 | 252.26 |
EV/EBIT |
— | 0.00 | — | — |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
— | 3.24 | — | — |
| Other line items | ||||
Depreciation/Fixed assets |
1.12 | 0.00 | 0.26 | 0.39 |
Cash ROIC |
48.16% | 32.81% | (8.25%) | (10.60%) |
Accounts Receivable Turnover |
— | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.53 | 1.22 | 1.41 |
Average Assets |
— | 90.51 | 171.62 | 244.74 |
Average Common Equity |
— | (80.57) | 65.07 | 229.53 |
Columns are period end dates